End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.71 CNY | -0.92% |
|
-1.22% | -32.85% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.85% | 218M | - | ||
-5.17% | 6.98B | B- | ||
+21.62% | 3.59B | B- | ||
-3.06% | 3.15B | B- | ||
+13.18% | 1.67B | - | ||
-7.81% | 1.19B | - | ||
-34.91% | 1.08B | B | ||
-36.76% | 1.05B | C- | ||
-32.83% | 875M | - | ||
-17.45% | 861M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300871 Stock
- Ratings Hvsen Biotechnology Co., Ltd.